SCHOTT Pharma KGaA Valuation
Is 1SXP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1SXP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1SXP (€25.62) is trading below our estimate of fair value (€30.6)
Significantly Below Fair Value: 1SXP is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1SXP?
Key metric: As 1SXP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 1SXP's PE Ratio? | |
|---|---|
| PE Ratio | 26.5x |
| Earnings | €150.41m |
| Market Cap | €3.99b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 17.2x |
| PEG Ratio | 1.7x |
Price to Earnings Ratio vs Peers
How does 1SXP's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 64.2x | ||
GXI Gerresheimer | 21.7x | 21.7% | €2.5b |
SRT3 Sartorius | 187.6x | 36.8% | €13.4b |
DMP Dermapharm Holding | 20.5x | 18.1% | €1.9b |
BIO3 Biotest | 26.9x | 82.7% | €1.4b |
1SXP SCHOTT Pharma KGaA | 25.7x | 15.9% | €4.0b |
Price-To-Earnings vs Peers: 1SXP is good value based on its Price-To-Earnings Ratio (25.7x) compared to the peer average (64.2x).
Price to Earnings Ratio vs Industry
How does 1SXP's PE Ratio compare vs other companies in the European Life Sciences Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 1SXP is good value based on its Price-To-Earnings Ratio (25.7x) compared to the European Life Sciences industry average (37.1x).
Price to Earnings Ratio vs Fair Ratio
What is 1SXP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 26.5x |
| Fair PE Ratio | 17.8x |
Price-To-Earnings vs Fair Ratio: 1SXP is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the estimated Fair Price-To-Earnings Ratio (17.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €25.62 | €34.76 +35.7% | 7.4% | €39.00 | €31.80 | n/a | 11 |
| Nov ’25 | €29.68 | €34.76 +17.1% | 7.4% | €39.00 | €31.80 | n/a | 11 |
| Oct ’25 | €30.54 | €34.76 +13.8% | 7.4% | €39.00 | €31.80 | n/a | 11 |
| Sep ’25 | €36.00 | €34.49 -4.2% | 11.3% | €44.00 | €30.00 | n/a | 11 |
| Aug ’25 | €32.10 | €34.21 +6.6% | 11.4% | €44.00 | €30.00 | n/a | 11 |
| Jul ’25 | €31.18 | €34.03 +9.1% | 11.2% | €44.00 | €30.00 | n/a | 11 |
| Jun ’25 | €29.30 | €34.84 +18.9% | 13.6% | €44.00 | €25.00 | n/a | 11 |
| May ’25 | €39.32 | €38.67 -1.7% | 12.5% | €45.00 | €30.00 | n/a | 10 |
| Apr ’25 | €39.60 | €38.31 -3.3% | 13.6% | €45.00 | €30.00 | n/a | 9 |
| Mar ’25 | €39.40 | €37.98 -3.6% | 13.5% | €45.00 | €30.00 | n/a | 8 |
| Feb ’25 | €36.60 | €33.54 -8.4% | 8.2% | €38.00 | €30.00 | n/a | 8 |
| Jan ’25 | €33.60 | €32.30 -3.9% | 9.2% | €37.00 | €27.50 | n/a | 8 |
| Dec ’24 | €28.80 | €31.91 +10.8% | 7.0% | €34.00 | €27.50 | n/a | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Aspen Pharmacare Holdings
R76.0b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.90
7D
-4.3%
1Y
4.7%
Fortrea Holdings
US$1.7b
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
K67
US$18.70
7D
-14.2%
1Y
-35.1%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.44
7D
-3.9%
1Y
-4.0%